Written informed consent, including confirmation of willingness to comply with all trial procedures
Body weight between 50 and 100 kg, and body mass index (BMI) between 18 and 30 kg/m\^2
Has not previously received navenibart
Not pregnant or breastfeeding and agreement to comply with requirements for pregnancy and breastfeeding, contraception use, and egg donation for the specified periods.
You may not be if
Prior or ongoing medical history, or results of a medical assessment, that the Investigator feels could result in a risk to the safety of the participant or the quality of data from the trial.
Key laboratory results outside of defined ranges
History or positive test results for tobacco, nicotine products, alcohol, marijuana (cannabis), or drugs of abuse
Receipt of other prohibited medications, biologic medications, or investigational products within defined windows prior to dosing
History of severe allergic reactions with an unknown cause
Donation of blood (at least 500 mL), or any amount of platelets or plasma within defined windows prior to dosing.
Known hypersensitivity to any component of navenibart
Any condition that the Investigator feels may affect the ability to provide written informed consent or demonstrates unwillingness or inability to comply with trial procedures